Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Keytruda plus chemotherapy should be a new standard of care as first-line therapy in patients with esophageal cancer, say researchers.
Opdivo and Keytruda are potential alternatives to current first-line therapies.
Keytruda plus chemotherapy reduced the risk of disease progression or death by 35% compared with chemotherapy alone in certain people.
Nearly half of patients treated with the combination saw their tumors shrink in an early study.
A third of people treated with the immunotherapy experienced remission.
A retrospective analysis showed that 29% of people with previously treated tumors responded to treatment.
“While our results are promising, a key limitation to this approach is that approximately 60 percent of patients still did not respond."
A study of melanoma patients found that treatment every six weeks is comparable to every three weeks.
“As far as we know, immunotherapy on its own would not make patients more susceptible to COVID-19."
Updated study results show antibody-drug conjugate plus Keytruda shrinks tumors in 73% of patients.
Immunotherapy may prolong survival compared with standard chemotherapy.
In a clinical trial, 46% of responding participants experienced a complete response lasting at least 12 months.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.